Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

Core Viewpoint - Myriad Genetics and PATHOMIQ have entered a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, an AI technology platform for prostate cancer, in the United States [1][5]. Group 1: Collaboration Details - The partnership aims to enhance Myriad's Oncology Solutions by integrating PATHOMIQ_PRAD, providing urologists and radiation oncologists with advanced molecular and AI-powered testing solutions [2][3]. - Myriad's existing offerings will be complemented by this collaboration, which aligns with NCCN guidelines for prostate cancer care [2]. Group 2: Technology and Innovation - PATHOMIQ's AI platform decodes complex morphological structures in cancer pathology, enabling rapid deployment of new use cases to predict patient outcomes and treatment responses [3][4]. - The AI model has demonstrated high prediction accuracy, outperforming existing markers in both Caucasian and African American patient cohorts [4]. Group 3: Market Impact and Future Plans - Myriad plans to commercially launch its first AI-driven prostate cancer clinical test later in 2025, aiming to provide personalized treatment options [5][10]. - The collaboration is expected to accelerate the development timelines for clinical validation of both Prolaris and PATHOMIQ_PRAD tests [4].